Does the media prefer ELVN or OCS?

In the previous week, Enliven Therapeutics had 1 more articles in the media than Oculis. MarketBeat recorded 5 mentions for Enliven Therapeutics and 4 mentions for Oculis. Oculis' average media sentiment score of 1.24 beat Enliven Therapeutics' score of 0.93 indicating that Oculis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oculis 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is OCS or VERA more profitable?

Vera Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Oculis' return on equity of -56.78% beat Vera Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oculis -8,460.67% -56.78% -45.62% Vera Therapeutics N/A -74.86% -60.18%

Does the media favor OCS or VERA?

In the previous week, Oculis had 2 more articles in the media than Vera Therapeutics. MarketBeat recorded 4 mentions for Oculis and 2 mentions for Vera Therapeutics. Oculis' average media sentiment score of 1.24 beat Vera Therapeutics' score of 0.32 indicating that Oculis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vera Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend OCS or RGC?

Oculis currently has a consensus price target of $38.33, suggesting a potential upside of 171.48%. Given Oculis' stronger consensus rating and higher probable upside, equities research analysts plainly believe Oculis is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oculis 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.80 Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, OCS or RGC?

Regencell Bioscience has lower revenue, but higher earnings than Oculis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oculis $1.45M 564.61 -$119.44M -$2.13 N/A Regencell Bioscience N/A N/A -$3.58M N/A N/A

Does the media refer more to OCS or RGC?

In the previous week, Oculis and Oculis both had 4 articles in the media. Oculis' average media sentiment score of 1.24 beat Regencell Bioscience's score of -0.41 indicating that Oculis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, OCS or QURE?

Oculis has higher earnings, but lower revenue than uniQure. uniQure is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oculis $1.45M 564.61 -$119.44M -$2.13 N/A uniQure $16.10M 163.79 -$198.97M -$3.48 N/A

Is OCS or QURE more profitable?

uniQure has a net margin of -1,154.42% compared to Oculis' net margin of -8,460.67%. Oculis' return on equity of -56.78% beat uniQure's return on equity. Company Net Margins Return on Equity Return on Assets Oculis -8,460.67% -56.78% -45.62% uniQure -1,154.42% -145.81% -27.15%

Does the media favor OCS or QURE?

In the previous week, uniQure had 20 more articles in the media than Oculis. MarketBeat recorded 24 mentions for uniQure and 4 mentions for Oculis. Oculis' average media sentiment score of 1.24 beat uniQure's score of 0.82 indicating that Oculis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive uniQure 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SLS or OCS?

In the previous week, SELLAS Life Sciences Group had 6 more articles in the media than Oculis. MarketBeat recorded 10 mentions for SELLAS Life Sciences Group and 4 mentions for Oculis. Oculis' average media sentiment score of 1.24 beat SELLAS Life Sciences Group's score of 0.72 indicating that Oculis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SELLAS Life Sciences Group 3 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oculis 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Oculis (OCS) Competitors

$14.12 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$14.02 -0.10 (-0.74%)

As of 07/2/2026 07:50 PM Eastern

Compare

OCS vs. ELVN, VERA, RGC, QURE, and SLS

Should you buy Oculis stock or one of its competitors? MarketBeat compares Oculis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oculis include Enliven Therapeutics (ELVN), Vera Therapeutics (VERA), Regencell Bioscience (RGC), uniQure (QURE), and SELLAS Life Sciences Group (SLS). These companies are all part of the "pharmaceutical products" industry.

How does Oculis compare to Enliven Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and Oculis (NASDAQ:OCS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 22.3% of Oculis shares are owned by institutional investors. 3.0% of Enliven Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Enliven Therapeutics had 1 more articles in the media than Oculis. MarketBeat recorded 5 mentions for Enliven Therapeutics and 4 mentions for Oculis. Oculis' average media sentiment score of 1.24 beat Enliven Therapeutics' score of 0.93 indicating that Oculis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oculis	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Enliven Therapeutics currently has a consensus target price of $67.83, indicating a potential upside of 36.16%. Oculis has a consensus target price of $38.33, indicating a potential upside of 171.48%. Given Oculis' higher probable upside, analysts clearly believe Oculis is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Enliven Therapeutics has higher earnings, but lower revenue than Oculis. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Oculis	$1.45M	564.61	-$119.44M	-$2.13	N/A

Enliven Therapeutics has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, Oculis has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market.

Enliven Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Enliven Therapeutics' return on equity of -21.04% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-21.04%	-20.41%
Oculis	-8,460.67%	-56.78%	-45.62%

Summary

Enliven Therapeutics beats Oculis on 10 of the 16 factors compared between the two stocks.

How does Oculis compare to Vera Therapeutics?

Oculis (NASDAQ:OCS) and Vera Therapeutics (NASDAQ:VERA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Vera Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Oculis' return on equity of -56.78% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-8,460.67%	-56.78%	-45.62%
Vera Therapeutics	N/A	-74.86%	-60.18%

22.3% of Oculis shares are held by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are held by institutional investors. 15.9% of Vera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Oculis has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45M	564.61	-$119.44M	-$2.13	N/A
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A

Oculis has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market.

Oculis presently has a consensus target price of $38.33, suggesting a potential upside of 171.48%. Vera Therapeutics has a consensus target price of $78.00, suggesting a potential upside of 89.32%. Given Oculis' stronger consensus rating and higher possible upside, equities analysts clearly believe Oculis is more favorable than Vera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Oculis had 2 more articles in the media than Vera Therapeutics. MarketBeat recorded 4 mentions for Oculis and 2 mentions for Vera Therapeutics. Oculis' average media sentiment score of 1.24 beat Vera Therapeutics' score of 0.32 indicating that Oculis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vera Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Oculis beats Vera Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Oculis compare to Regencell Bioscience?

Oculis (NASDAQ:OCS) and Regencell Bioscience (NASDAQ:RGC) are both pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

Oculis has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.84, indicating that its stock price is 84% more volatile than the broader market.

In the previous week, Oculis and Oculis both had 4 articles in the media. Oculis' average media sentiment score of 1.24 beat Regencell Bioscience's score of -0.41 indicating that Oculis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

22.3% of Oculis shares are held by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are held by institutional investors. 2.0% of Regencell Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Regencell Bioscience has lower revenue, but higher earnings than Oculis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45M	564.61	-$119.44M	-$2.13	N/A
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

Regencell Bioscience has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Regencell Bioscience's return on equity of 0.00% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-8,460.67%	-56.78%	-45.62%
Regencell Bioscience	N/A	N/A	N/A

Oculis currently has a consensus price target of $38.33, suggesting a potential upside of 171.48%. Given Oculis' stronger consensus rating and higher probable upside, equities research analysts plainly believe Oculis is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Oculis and Regencell Bioscience tied by winning 6 of the 12 factors compared between the two stocks.

How does Oculis compare to uniQure?

Oculis (NASDAQ:OCS) and uniQure (NASDAQ:QURE) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

Oculis currently has a consensus price target of $38.33, indicating a potential upside of 171.48%. uniQure has a consensus price target of $64.17, indicating a potential upside of 53.47%. Given Oculis' stronger consensus rating and higher possible upside, equities research analysts plainly believe Oculis is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
uniQure	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65

uniQure has a net margin of -1,154.42% compared to Oculis' net margin of -8,460.67%. Oculis' return on equity of -56.78% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-8,460.67%	-56.78%	-45.62%
uniQure	-1,154.42%	-145.81%	-27.15%

In the previous week, uniQure had 20 more articles in the media than Oculis. MarketBeat recorded 24 mentions for uniQure and 4 mentions for Oculis. Oculis' average media sentiment score of 1.24 beat uniQure's score of 0.82 indicating that Oculis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
uniQure	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oculis has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market. Comparatively, uniQure has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market.

Oculis has higher earnings, but lower revenue than uniQure. uniQure is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45M	564.61	-$119.44M	-$2.13	N/A
uniQure	$16.10M	163.79	-$198.97M	-$3.48	N/A

22.3% of Oculis shares are owned by institutional investors. Comparatively, 78.8% of uniQure shares are owned by institutional investors. 4.7% of uniQure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Oculis and uniQure tied by winning 8 of the 16 factors compared between the two stocks.

How does Oculis compare to SELLAS Life Sciences Group?

SELLAS Life Sciences Group (NASDAQ:SLS) and Oculis (NASDAQ:OCS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

SELLAS Life Sciences Group has higher earnings, but lower revenue than Oculis. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A
Oculis	$1.45M	564.61	-$119.44M	-$2.13	N/A

SELLAS Life Sciences Group has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. SELLAS Life Sciences Group's return on equity of -47.12% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%
Oculis	-8,460.67%	-56.78%	-45.62%

SELLAS Life Sciences Group has a beta of 2.42, meaning that its stock price is 142% more volatile than the broader market. Comparatively, Oculis has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market.

In the previous week, SELLAS Life Sciences Group had 6 more articles in the media than Oculis. MarketBeat recorded 10 mentions for SELLAS Life Sciences Group and 4 mentions for Oculis. Oculis' average media sentiment score of 1.24 beat SELLAS Life Sciences Group's score of 0.72 indicating that Oculis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SELLAS Life Sciences Group	3 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oculis	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SELLAS Life Sciences Group currently has a consensus target price of $10.00, suggesting a potential downside of 33.24%. Oculis has a consensus target price of $38.33, suggesting a potential upside of 171.48%. Given Oculis' stronger consensus rating and higher probable upside, analysts clearly believe Oculis is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. Comparatively, 22.3% of Oculis shares are owned by institutional investors. 1.3% of SELLAS Life Sciences Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

SELLAS Life Sciences Group beats Oculis on 8 of the 15 factors compared between the two stocks.

Get Oculis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OCS vs. The Competition

Export

Metric	Oculis	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$818.73M	$3.78B	$7.18B	$12.47B
Dividend Yield	N/A	2.16%	2.67%	6.51%
P/E Ratio	-6.63	21.61	28.02	24.70
Price / Sales	564.61	325.99	534.82	99.69
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	3.46	8.66	10.96	6.46
Net Income	-$119.44M	$23.81M	$3.57B	$337.01M
7 Day Performance	17.67%	3.39%	2.12%	1.69%
1 Month Performance	25.96%	10.81%	5.25%	3.81%
1 Year Performance	-25.51%	62.61%	33.29%	23.90%

Oculis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OCS Oculis	3.5428 of 5 stars	$14.12 flat	$38.33 +171.5%	-25.5%	$818.73M	$1.45M	N/A	2	News Coverage Short Interest Increase
ELVN Enliven Therapeutics	3.4153 of 5 stars	$51.18 +0.6%	$64.50 +26.0%	+141.0%	$3.12B	N/A	N/A	50	Analyst Forecast Gap Down
VERA Vera Therapeutics	3.1597 of 5 stars	$43.35 +0.5%	$78.00 +79.9%	+73.5%	$3.11B	N/A	N/A	40	Gap Up
RGC Regencell Bioscience	0.3614 of 5 stars	$6.21 +0.2%	N/A	-72.3%	$3.07B	N/A	N/A	10	Gap Up
QURE uniQure	3.5677 of 5 stars	$45.96 -3.0%	$64.17 +39.6%	+188.6%	$2.90B	$16.10M	N/A	500	Insider Trade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OCS) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oculis (OCS) Competitors

OCS vs. ELVN, VERA, RGC, QURE, and SLS

How does Oculis compare to Enliven Therapeutics?

Summary

How does Oculis compare to Vera Therapeutics?

Summary

How does Oculis compare to Regencell Bioscience?

Summary

How does Oculis compare to uniQure?

Summary

How does Oculis compare to SELLAS Life Sciences Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCS vs. The Competition

Oculis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oculis (OCS) Competitors

OCS vs. ELVN, VERA, RGC, QURE, and SLS

How does Oculis compare to Enliven Therapeutics?

Do insiders & institutionals have more ownership in ELVN or OCS?

Does the media prefer ELVN or OCS?

Do analysts prefer ELVN or OCS?

Which has better earnings & valuation, ELVN or OCS?

Which has more volatility & risk, ELVN or OCS?

Is ELVN or OCS more profitable?

Summary

How does Oculis compare to Vera Therapeutics?

Is OCS or VERA more profitable?

Do institutionals & insiders hold more shares of OCS or VERA?

Which has stronger valuation & earnings, OCS or VERA?

Which has more volatility & risk, OCS or VERA?

Do analysts recommend OCS or VERA?

Does the media favor OCS or VERA?

Summary

How does Oculis compare to Regencell Bioscience?

Which has more risk and volatility, OCS or RGC?

Does the media refer more to OCS or RGC?

Do insiders & institutionals hold more shares of OCS or RGC?

Which has better earnings and valuation, OCS or RGC?

Is OCS or RGC more profitable?

Do analysts recommend OCS or RGC?

Summary

How does Oculis compare to uniQure?

Do analysts rate OCS or QURE?

Is OCS or QURE more profitable?

Does the media favor OCS or QURE?

Which has more volatility and risk, OCS or QURE?

Which has higher valuation and earnings, OCS or QURE?

Do institutionals & insiders believe in OCS or QURE?

Summary

How does Oculis compare to SELLAS Life Sciences Group?

Which has better earnings & valuation, SLS or OCS?

Is SLS or OCS more profitable?

Which has more risk & volatility, SLS or OCS?

Does the media prefer SLS or OCS?

Do analysts rate SLS or OCS?

Do institutionals and insiders hold more shares of SLS or OCS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCS vs. The Competition

Oculis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools